Mutant ALK Kinase Detection via Segmented FISH and PCR Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective identification and targeting of novel gene mutations in human cancers, particularly in non-small cell lung carcinoma (NSCLC), which limits the development of specific therapeutics and diagnostics.
Innovation Solution
Identification of novel gene deletion mutations resulting in fusion proteins combining Anaplastic Lymphoma Kinase (ALK) with Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fused Gene (TFG), along with the development of methods and reagents for detecting these mutant ALK kinases in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection methods are used for identifying gene mutations in NSCLC, then the detection process is simple and quick, but the detection precision and ability to identify novel mutations is insufficient
Solution Approach 1:
The patent segments the detection process into multiple specialized components: FISH probes for translocation detection, PCR assays for fusion gene amplification, and sequencing methods for mutation identification. Each component targets specific aspects of mutation detection, collectively achieving high precision without requiring a single complex system
Solution Approach 2:
The patent introduces intermediary molecules and reagents such as fluorescently labeled probes, PCR primers, and hybridization buffers that mediate between the sample and detection instruments. These intermediaries enable precise detection of mutant ALK kinases while keeping the overall methodology accessible and implementable in clinical settings
2Measurement precision
If comprehensive detection methods are developed to identify all mutant ALK kinases, then the detection precision and coverage improve, but the time required for diagnosis and treatment planning increases
Solution Approach 1:
The patent employs preliminary enrichment steps where FISH probes or PCR primers specifically target and amplify ALK fusion transcripts before full sequencing. This preliminary action concentrates the signal from mutant ALK kinases, enabling accurate identification with reduced sequencing depth requirements and faster turnaround time
Solution Approach 2:
The patent implements a staged detection approach where initial screening uses rapid FISH or PCR methods to identify patients with ALK fusions, followed by periodic or selective deeper sequencing only for positive cases. This periodic action reduces overall diagnostic time while maintaining high identification accuracy for the target population
3Adaptability or versatility
If specific reagents and methods are developed for each novel mutation, then the therapeutic targeting precision improves, but the device and assay complexity increases
Solution Approach 1:
The patent develops universal detection platforms that can identify multiple types of ALK fusions and mutations through a single assay system. The FISH probes and PCR primers are designed to detect various fusion partners (EML4, TFG, others) simultaneously, providing versatile therapeutic targeting capability without requiring separate assays for each mutation type
Solution Approach 2:
The patent utilizes parameter changes in probe and primer design to achieve specificity across multiple mutation types. By adjusting hybridization conditions, probe sequences, and amplification parameters, a single assay system can differentiate and detect various mutant ALK kinases, maintaining assay simplicity while expanding therapeutic targeting options
Data Source
AI summary
Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.